This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.
By MICHAEL MILLENSON A Rock Health write-up of this year’s Epic Users Group Meeting captured the artificial intelligence vibe with a play on the names of three new AI chatbots rolled out by the country’s dominant electronic health record firm. “Epic Goes APE (Art, Penny and Emmie),” read the headline, using the first letters of…
By JOHN SAMARAS A US retail pharmacy pays $1,302 to acquire one month of branded Wegovy. That figure comes from the Centers for Medicare and Medicaid Services National Average Drug Acquisition Cost file, effective August 19, 2026, for the 25 mg oral tablet at 30 tablets a month. The cheapest cash price I verified on…
The latest KFF Survey of Immigrants finds that immigrants’ worries about detention or deportation have risen sharply since 2023, even among lawfully present immigrants and naturalized citizens. This poll finding includes new insights about immigrants’ attitudes and experiences during the early days of President Trump’s second term.
Here is a selection of recent executive hires, exits, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.
Quinn Cochran-Zipp went to the emergency room three times with severe abdominal pain before doctors figured out she had early-stage cancer in the germ cells of her right ovary. After emergency surgery four years ago, the Greeley, Colorado, lab technician is cancer-free. The two hospitals that treated Cochran-Zipp at the time determined that she qualified…
[Sponsored] Discover the top-rated Medicaid planning lawyers who help families protect assets, provide quality care and navigate elder law with confidence. The post The 5 Top-Rated Medicaid Planning Lawyers appeared first on MedCity News.
Successful organizations standardize workflows, invest in staff training, and establish data governance
Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a key pathway in the peripheral nervous system. The post Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds…
The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication. The post Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin…